VCA
TMO icon

Verdence Capital Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Verdence Capital Advisors’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.63M Buy
9,423
+994
+12% +$539K 0.27% 92
2025
Q4 		$4.88M Buy
8,429
+197
+2% +$111K 0.29% 79
2025
Q3 		$4.64M Buy
8,232
+3,751
+84% +$1.75M 0.27% 89
2025
Q2 		$1.82M Buy
4,481
+248
+6% +$104K 0.12% 174
2025
Q1 		$2.11M Buy
4,233
+456
+12% +$247K 0.16% 140
2024
Q4 		$1.96M Sell
3,777
-270
-7% -$148K 0.16% 157
2024
Q3 		$2.5M Buy
4,047
+174
+4% +$103K 0.2% 134
2024
Q2 		$2.14M Buy
3,873
+2
+0.1% +$1.15K 0.19% 139
2024
Q1 		$2.25M Buy
3,871
+3
+0.1% +$1.68K 0.2% 132
2023
Q4 		$2.05M Buy
3,868
+58
+2% +$28.1K 0.2% 128
2023
Q3 		$1.93M Buy
3,810
+267
+8% +$142K 0.21% 131
2023
Q2 		$1.85M Sell
3,543
-120
-3% -$64.8K 0.21% 120
2023
Q1 		$2.11M Buy
3,663
+959
+35% +$541K 0.26% 106
2022
Q4 		$1.49M Buy
2,704
+888
+49% +$471K 0.18% 130
2022
Q3 		$921K Buy
1,816
+106
+6% +$59.3K 0.13% 179
2022
Q2 		$929K Buy
1,710
+67
+4% +$36.9K 0.12% 186
2022
Q1 		$971K Buy
1,643
+50
+3% +$28.7K 0.11% 200
2021
Q4 		$1.06M Buy
1,593
+67
+4% +$41.8K 0.13% 171
2021
Q3 		$872K Buy
1,526
+615
+68% +$338K 0.11% 191
2021
Q2 		$460K Sell
911
-67
-7% -$31.6K 0.06% 265
2021
Q1 		$446K Sell
978
-45
-4% -$21.5K 0.08% 249
2020
Q4 		$477K Sell
1,023
-26
-2% -$12.2K 0.09% 215
2020
Q3 		$463K Sell
1,049
-2
-0.2% -$826 0.11% 200
2020
Q2 		$381K Buy
1,051
+39
+4% +$13.1K 0.09% 211
2020
Q1 		$287K Sell
1,012
-122
-11% -$38.5K 0.09% 214
2019
Q4 		$369K Buy
1,134
+44
+4% +$13.3K 0.09% 210
2019
Q3 		$318K Hold
1,090
– – 0.09% 223
2019
Q2 		$320K Buy
1,090
+44
+4% +$12.1K 0.09% 215
2019
Q1 		$286K Buy
+1,046
New +$260K 0.08% 210

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Verdence Capital Advisors's TMO Position: Q1 2026 in Review

Verdence Capital Advisors increased its Thermo Fisher Scientific (TMO) stake by 12% in Q1 2026, buying an estimated $539K and bringing the position to 9,423 shares worth $4.63M. The position accounts for 0.27% of the portfolio, ranked #92.

Verdence Capital Advisors first reported a position in TMO in Q1 2019 and has held it in 29 quarters since. The position peaked at $4.88M in Q4 2025. 2,588 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Verdence Capital Advisors held 9,423 shares of Thermo Fisher Scientific worth $4.63M as of Q1 2026.
  • Verdence Capital Advisors bought 994 Thermo Fisher Scientific shares in Q1 2026, an estimated $539K.
  • Thermo Fisher Scientific made up 0.27% of Verdence Capital Advisors's portfolio in Q1 2026, its #92 holding.
  • Verdence Capital Advisors first reported a position in Thermo Fisher Scientific in Q1 2019 and has held it in 29 quarters since.
  • Verdence Capital Advisors's Thermo Fisher Scientific position peaked at $4.88M in Q4 2025.
  • 2,588 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.